Literature DB >> 9484867

The damaging role of bacteria in chronic lung infection.

P Cole1.   

Abstract

Because of their embryological derivation from foregut the respiratory airways are regularly host to bacteria arriving in inspired air and aspirated from the naso-oropharynx. Should the first-line defence (mucociliary clearance) be less than perfect, such bacteria remain longer in the airway mucus and some are able to capitalize on this delay by compromising mucus transport further through the production of epithelium-damaging cilioinhibitory and ciliotoxic substances. Bacterial persistence in the airways elicits an inflammatory host response which causes further damage to the airway and results in a 'vicious circle' of progressive lung damage. Treatment hinges upon eliminating the bacteria in the mucus using antibiotics that penetrate mucus well (e.g. fluoroquinolones)--and considering adjunct therapy with anti-inflammatory and mucokinetic agents.

Entities:  

Mesh:

Year:  1997        PMID: 9484867     DOI: 10.1093/jac/40.suppl_1.5

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

Review 1.  Interventions for bronchiectasis: an overview of Cochrane systematic reviews.

Authors:  Emma J Welsh; David J Evans; Stephen J Fowler; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

2.  E2f4 is required for normal development of the airway epithelium.

Authors:  Paul S Danielian; Carla F Bender Kim; Alicia M Caron; Eliza Vasile; Roderick T Bronson; Jacqueline A Lees
Journal:  Dev Biol       Date:  2007-03-03       Impact factor: 3.582

Review 3.  From hemp seed and porcupine quill to HRCT: advances in the diagnosis and epidemiology of bronchiectasis.

Authors:  D A Spencer
Journal:  Arch Dis Child       Date:  2005-07       Impact factor: 3.791

4.  Outcomes in children treated for persistent bacterial bronchitis.

Authors:  Deirdre Donnelly; Anita Critchlow; Mark L Everard
Journal:  Thorax       Date:  2006-11-14       Impact factor: 9.139

Review 5.  Intermittent prophylactic antibiotics for bronchiectasis.

Authors:  Sally Spencer; Tim Donovan; James D Chalmers; Alexander G Mathioudakis; Melissa J McDonnell; Anthony Tsang; Peter Leadbetter
Journal:  Cochrane Database Syst Rev       Date:  2022-01-05

Review 6.  Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.

Authors:  Sanjay H Chotirmall; Maria Teresa Martin-Gomez
Journal:  Mycopathologia       Date:  2017-05-17       Impact factor: 2.574

7.  The need to redefine non-cystic fibrosis bronchiectasis in childhood.

Authors:  K M Eastham; A J Fall; L Mitchell; D A Spencer
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

8.  Tomosynthesis in pulmonary cystic fibrosis with comparison to radiography and computed tomography: a pictorial review.

Authors:  Kristina Vult von Steyern; Isabella Björkman-Burtscher; Mats Geijer
Journal:  Insights Imaging       Date:  2011-11-11

Review 9.  Dual antibiotics for bronchiectasis.

Authors:  Lambert M Felix; Seamus Grundy; Stephen J Milan; Ross Armstrong; Haley Harrison; Dave Lynes; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-06-11

Review 10.  Continuous versus intermittent antibiotics for bronchiectasis.

Authors:  Tim Donovan; Lambert M Felix; James D Chalmers; Stephen J Milan; Alexander G Mathioudakis; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.